Migraine Excellence Hub

Excellence Forum

Leaders in the field share expert insights and institutional best practices.

Pearls of Wisdom

Research Summaries

Conference Coverage

Conference Coverage

AAN 2026: Post Hoc Interim Analysis Shows Atogepant Weight Loss

04/22/2026

Anthony Calabro, MA

Post hoc subgroup analysis of interim phase 3 data shows weight loss with atogepant in migraine and overweight or obesity.

04/22/2026

Conference Coverage

Conference Coverage

OnabotulinumtoxinA vs Topiramate for Chronic Migraine: Higher Patient Satisfaction Reported in US FORWARD Study

04/20/2026

Ashton L. Stahl

Physicians managing chronic migraine may be interested in new comparative patient-reported data from the FORWARD study, which evaluated treatment satisfaction with onabotulinumtoxinA versus topiramate. In...

04/20/2026

Conference Coverage

Conference Coverage

GLP-1 Receptor Agonists Associated With Lower Healthcare Utilization in Chronic Migraine

04/20/2026

Anthony Calabro, MA

At the 2026 American Academy of Neurology Annual Meeting in Chicago, IL, investigators presented real-world evidence evaluating whether glucagon-like peptide-1 receptor agonists influence healthcare...

04/20/2026

Research Summary

Research Summary

Ultrasound-Guided Nerve Blocks Show Comparable Efficacy in Chronic Resistant Migraine, Added Benefits in Select Patients

03/09/2026

Kate Young

The results from a recent randomized controlled trial showed that ultrasound-guided sphenopalatine ganglion (SPG) and greater occipital nerve blocks are equally effective in reducing headache frequency,...

03/09/2026

Research Summary

Research Summary

Safety, Tolerability of Once-Daily Rimegepant for Episodic Migraine Prevention in US Adults

02/26/2026

Ashton L. Stahl

This phase 4 study assessed the long-term safety and tolerability of once-daily oral rimegepant (75 mg) in adults with episodic migraine to inform clinicians about its preventive treatment profile.

02/26/2026

April 2026

Current Issue

April 2026